HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAapproval95% confidence

Withdrawn | Cancer Accelerated Approvals

Source: FDA

Why This Matters

Why this matters: illustrates how regulators handled a comparable approval decision relevant to Sodium Bicarbonate; the same agency is already in play for this signal, so precedent weight is higher.

Regulatory Analysis

This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been subsequently withdrawn, and are therefore, no longer FDA-approved.

Supporting Context

Therapeutic area
Metabolic Disorders · Electrolyte Replenisher
Sub-indication
General

Related signal: FDA Grants Approval for Sodium Bicarbonate ANDA219089 by Milla Pharms

Source

View source document

Related Signal

Open signal — FDA Grants Approval for Sodium Bicarbonate ANDA219089 by Milla Pharms
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.